Updated September 3 at 7:03pm

R.I. to receive $200K in Wyeth Pharmaceuticals settlement

Rhode Island will share in a $491 million settlement payout by Wyeth Pharmaceuticals Inc., Attorney General Peter F. Kilmartin announced Tuesday.

To continue reading this article, please do one of the following.



Enter your email to receive Providence Business News' e-newsletters
and breaking news alerts.  

Health Care

R.I. to receive $200K in Wyeth Pharmaceuticals settlement

Posted:

PROVIDENCE – Rhode Island will share in a $491 million settlement payout by Wyeth Pharmaceuticals Inc., Attorney General Peter F. Kilmartin announced Tuesday. The state’s share will be $201,502.

The settlement is to resolve civil and criminal allegations that Wyeth promoted the sale and use of the kidney transplant drug Rapamune for uses not approved by the FDA.

Rapamune is prescribed to prevent the body from rejecting a donor kidney that has been transplanted into the body. Complaints filed in U.S. District Courts allege Wyeth knowingly promoted the drug for use with other types of organ transplants and for patients who had already taken other immunosuppressant drugs.

“The establishment and enforcement of federal rules and regulations for the marketing and use of drugs is to protect the health and safety of patients, yet pharmaceutical companies continue to bypass federal controls to protect their profits,” said Kilmartin.

Wyeth pled guilty to the criminal charges.

Wyeth is a subsidiary of Pfizer. The pharmaceuticals giant acquired the company after the off-label marketing occurred.

health, health care, wyeth, rapamune, peter f. kilmartin, pfizer

Comments

No comments on this story | Please log in to comment by clicking here
Please log in or register to add your comment
Latest News